OR WAIT 15 SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
End-to-End Cell Therapy Automation: An Immunotherapy Case Study
Yaling Shi
Yaling Shi is senior manager R&T, Lonza Inc.
James B Morrissey
James B Morrissey is bioengineering scientist-Cocoon Program, Octane Biotech Inc.
Nuala Trainor
Nuala Trainor is director of Biological Programs, Octane Biotech Inc.
Consider automation early in the rollout of clinical translation and scale up of clinical-trial protocols.
As anticipation builds about accelerated clinical adoption of advanced cell therapies, more attention is turning to the underlying manufacturing strategies that will allow these therapies to benefit patients worldwide. While cell therapies hold great promise clinically, high manufacturing costs relative to reimbursement present a formidable roadblock to commercialization. Therefore, the need for cost effectiveness, process efficiency, and product consistency is driving efforts for automation in numerous cell therapy fields and particularly for T-cell immunotherapies.
Download the
.
Article Details
BioPharm International
eBook: Development Strategies for Emerging Therapies
Vol. 30
September 2017
Pages: 10–18
Citation
When referring to this article, please cite it as J. Morrissey, N. Trainor, and Y. Shi, "End-to-End Cell Therapy Automation: An Immunotherapy Case Study," BioPharm International Development Strategies for Emerging Therapies eBook (September 2017).